ES-SCLC
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
ES-SCLC
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
May 19, 2024, 10:49 |
Societies
Laurie Fenton Ambrose explains breakthrough advance in extensive-stage small cell lung cancer - Amgen Oncology
Amgen Oncology shared on LinkedIn: “A breakthrough advance in extensive-stage small cell lung cancer (ES-SCLC)…
May 18, 2024, 02:46 |
Drugs
Vivek Subbiah: US FDA granted accelerated approval to tarlatamab-dlle
Vivek Subbiah shared on X: "New FDA Approval. Today the US FDA granted accelerated approval…
Apr 2, 2024, 05:10 |
Blog
Chul Kim: March has been fruitful and rewarding, as we launched two IITs of ADC back to back!
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared on X/Twitter: "March has been fruitful…
Sep 27, 2023, 16:57 |
Blog
Hidehito Horinouchi: Reconsidering the cutoff for sensitive and refractory relapses in ES-SCLC in the era of ICIs in JTO and JTO CRR by Dr. Masahiro Torasawa.
Hidehito Horinouchi, Assistant Chief of the Department of Thoracic Oncology at National Cancer Center Hospital,…
All:
5
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube